Stanford University
Showing 21-30 of 54 Results
-
Joyce Teng, MD, PhD
Professor of Dermatology and, by courtesy, of Pediatrics
BioJoyce Teng, MD, PhD is a professor in dermatology at Stanford University. She is affiliated with multiple hospitals in the area, including Lucile Salter Packard Children's Hospital (LPCH) at Stanford and Stanford Hospital and Clinics (SHC). She received her medical degree from Vanderbilt University School of Medicine and has been in practice for more than 12 years. She is one of the 6 pediatric dermatologists practicing at LPCH and one of 72 at SHC who specialize in Dermatology. She sees patients with rare genetic disorders, birthmarks, vascular anomalies and a variety of inflammatory skin diseases. She is also an experienced pediatric dermatological surgeon. Her research interests are drug discovery and novel therapy for skin disorders.
-
Swaraj Thaman
Life Science Research Professional, Pediatrics - Endocrinology
Current Role at StanfordLife Science Research Professional 1, Translational Genomics of Diabetes Laboratory, Department of Pediatrics - Endocrinology, School of Medicine
-
George F Tidmarsh
Adjunct Professor, Pediatrics - Neonatology
BioDr. Tidmarsh received M.D. and Ph.D. from Stanford University, where he also completed fellowship training in Pediatric Oncology and Neonatology and is currently Adjunct Faculty of Pediatrics and Neonatology. He served as clinical faculty at Stanford for a number of years after fellowship prior to devoting his full time to clinical research and development in order to bring new treatments through the FDA approval process. Dr. Tidmarsh was President, Chief Executive Officer, Secretary and a Director of La Jolla Pharmaceutical Company from January 2012 until November 2019. While at La Jolla, Dr. Tidmarsh helped discover the use of angiotensin II for the treatment of shock and led all aspects of the development including approval by the US FDA and the EMA for the treatment of patients suffering from distributive shock. He also led the development of artesunate for the treatment of severe malaria, now pending action for potential approval at the FDA. Dr. Tidmarsh has over 30 years of experience in biotechnology, including the successful clinical development of three FDA-approved drugs. He previously served as the Chief Executive Officer of Horizon Pharma, Inc., a company he founded in 2005. While at Horizon, he led all aspects of development of Duexis, which was approved by the FDA for the treatment of rheumatoid arthritis. He also founded Threshold Pharmaceuticals, Inc. and held senior positions at Coulter Pharmaceutical, Inc. (acquired by GlaxoSmithKline) and SEQUUS Pharmaceuticals, Inc. (acquired by Johnson & Johnson). While at Coulter and SEQUUS, Dr. Tidmarsh led the clinical development of BEXXAR and Doxil, respectively, two FDA-approved anti-cancer agents.
At Stanford, Dr. Tidmarsh is devoted to teaching clinical research and development to residents, fellows and junior faculty. In addition, he is working to help improve the quality of medical care through various efforts which include serving on the board of Lucile Packard Foundation for Children's Health. -
Christina (Christy) Tise, MD, PhD
Assistant Professor of Pediatrics (genetics)
BioDr. Christina (Christy) Tise is a physician scientist and Assistant Professor in the Division of Medical Genetics at Stanford with subspecialty training in Clinical Biochemical Genetics. Dr. Tise has developed multiple research projects focused on the clinical impact of biochemical genetic conditions in pregnancy and newborn health, including a project focused on unforeseen diagnoses in individuals initially identified through state newborn screening which has resulted in a number of publications.
Dr. Tise also researches the genetic etiologies of recurrent pregnancy loss and the impact of inherited metabolic conditions on human reproduction. She is involved in several research initiatives including contributing to the development of TRIOS, a multi-site, NIH-funded research study to evaluate the genetic causes of recurrent pregnancy loss. In serving as the primary research mentor for a recent Masters of Genetic Counseling graduate, Dr. Tise’s research on carrier and newborn screening has highlighted areas of ancestry-related healthcare inequities specific to the field of Medical Genetics.
Dr. Tise’s primary academic and advocacy interests are embodied in this work, specifically the overlap between biochemical and molecular analysis, and the clinical utility of innovative technologies for diagnosis and treatment of genetic disease. This is an unbelievably thrilling time for the field of Medical Genetics, as it promises immense progress and opportunity for all fields of medicine, and Dr. Tise is determined, honored, and incredibly excited to be a part of it!
Research interests: newborn screening, carrier screening, prenatal screening, genetics of recurrent pregnancy loss, biochemical genetics, novel gene discovery, variant interpretation, founder populations, diagnostic genetic testing, bioethics, GWAS/ExWAS
